uniQure N.V. (QURE)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1590560 · fiscal year ends in Dec
Closing price $25.27 on 29 Oct 2026; 52-week range $9.03 to $70.59.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $18.7M
- Revenue growth
- 30.2%
- Net income, last twelve months
- -$252.2M
- Earnings per share
- -$4.02
- Gross margin
- 92.5%
- Operating margin
- -1071.5%
- Net margin
- -1350.7%
- Return on equity
- -77.8%
- Market value
- $1.8B
- Cash
- $413.0M
- Debt
- $50.1M
- Debt to equity
- 0.15
- Shares outstanding
- 69.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $16.1M | -$185.3M | -$199.0M | -$3.46 | -$178.4M | 10-K filed 2 Mar 2026 |
| FY2024 | 31 Dec 2024 | $27.1M | -$184.3M | -$239.6M | -$4.92 | -$186.1M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $15.8M | -$282.9M | -$308.5M | -$6.47 | -$153.1M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $106.5M | -$143.2M | -$126.8M | -$2.71 | -$162.7M | 10-K filed 27 Feb 2023 |
| FY2021 | 31 Dec 2021 | $524.0M | $310.6M | $329.6M | $7.04 | $270.5M | 10-K filed 25 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $5.8M | -$81.1M | -$1.22 |
| Q1 FY2026 | 31 Mar 2026 | $3.6M | -$53.5M | -$0.85 |
| Q4 FY2025 | 31 Dec 2025 | $5.6M | -$37.1M | -$0.57 |
| Q3 FY2025 | 30 Sep 2025 | $3.7M | -$80.5M | -$1.38 |
| Q2 FY2025 | 30 Jun 2025 | $5.3M | -$37.7M | -$0.69 |
| Q1 FY2025 | 31 Mar 2025 | $1.6M | -$43.6M | -$0.82 |
| Q4 FY2024 | 31 Dec 2024 | $5.2M | -$73.3M | -$1.49 |
| Q3 FY2024 | 30 Sep 2024 | $2.3M | -$44.4M | -$0.91 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| License revenues | $15.9M | 99.0% |
| Collaboration revenues | $164.0K | 1.0% |
Company events
The newest 8-K filings of 154 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 29 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 2 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 29 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Jun 2026 | 8-K | Material agreement, Other events | 1.01, 8.01, 9.01 |
| 22 Jun 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 17 Jun 2026 | 8-K | Other events | 8.01, 9.01 |
| 15 Jun 2026 | 8-K | Leadership change, Shareholder vote, Bylaws or fiscal year change | 5.02, 5.03, 5.07, 9.01 |
| 5 May 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 2 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 13 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 9 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 342 held.
| Filed | Form | Period |
|---|---|---|
| 29 Sep 2026 | 8-K | 29 Sep 2026 |
| 2 Sep 2026 | 8-K | 2 Sep 2026 |
| 29 Jul 2026 | S-8 | – |
| 29 Jul 2026 | 10-Q | 30 Jun 2026 |
| 29 Jul 2026 | 8-K | 29 Jul 2026 |
| 24 Jun 2026 | 8-K | 23 Jun 2026 |
| 22 Jun 2026 | 8-K | 19 Jun 2026 |
| 17 Jun 2026 | 8-K | 17 Jun 2026 |
| 15 Jun 2026 | 8-K | 10 Jun 2026 |
| 5 May 2026 | 10-Q | 31 Mar 2026 |
| 5 May 2026 | 8-K | 5 May 2026 |
| 30 Apr 2026 | 8-K | 30 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Jul 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 9,200 | $44.43 | $408.8K | 531,109 | 7 Jul 2026 |
| 2 Jul 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 4,282 | $45.43 | $194.5K | 526,827 | 7 Jul 2026 |
| 2 Jul 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 7,600 | $45.89 | $348.8K | 519,227 | 7 Jul 2026 |
| 30 Jun 2026 | Abi-Saab Walid, Chief Medical Officer | Sale under a trading plan | 10,000 | $46.46 | $464.6K | 168,235 | 2 Jul 2026 |
| 30 Jun 2026 | Abi-Saab Walid, Chief Medical Officer | Sale under a trading plan | 20,000 | $46.40 | $928.0K | 148,235 | 2 Jul 2026 |
| 30 Jun 2026 | Kaye Jack, Director | Sale under a trading plan | 4,107 | $46.49 | $190.9K | 25,996 | 2 Jul 2026 |
| 30 Jun 2026 | Kaye Jack, Director | Sale under a trading plan | 17,060 | $46.43 | $792.1K | 25,996 | 2 Jul 2026 |
| 26 Jun 2026 | Abi-Saab Walid, Chief Medical Officer | Sale outside a trading plan | 1,434 | $46.86 | $67.2K | 168,235 | 30 Jun 2026 |
| 25 Jun 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 28,716 | $50.02 | $1.4M | 519,227 | 26 Jun 2026 |
| 24 Jun 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 6,696 | $50.00 | $334.8K | 519,227 | 26 Jun 2026 |
| 18 Jun 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 4,656 | $50.00 | $232.8K | 558,810 | 22 Jun 2026 |
| 18 Jun 2026 | Kapusta Matthew C, CEO, Managing Director | Sale under a trading plan | 37,015 | $50.00 | $1.9M | 521,795 | 22 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Jul 2026 | Kapusta Matthew C, Officer, Director, CEO AND MANAGING DIRECTOR | 21,082 | $951.9K | 2 Jul 2026 |
| 30 Jun 2026 | Kaye Jack, Director | 21,167 | $983.0K | 30 Jun 2026 |
| 30 Jun 2026 | Abi-Saab Walid, Chief Medical Officer | 30,000 | $1.4M | 30 Jun 2026 |
| 26 Jun 2026 | Abi-Saab Walid, Chief Medical Officer | 1,434 | $67.2K | 26 Jun 2026 |
| 25 Jun 2026 | Kapusta Matthew C, Officer, Director, CEO AND MANAGING DIRECTOR | 28,716 | $1.4M | 25 Jun 2026 |
| 24 Jun 2026 | Kapusta Matthew C, Officer, Director, CEO AND MANAGING DIRECTOR | 6,696 | $334.8K | 24 Jun 2026 |
| 18 Jun 2026 | Kapusta Matthew C, Officer, Director, CEO AND MANAGING DIRECTOR | 41,671 | $1.9M | 18 Jun 2026 |
| 17 Jun 2026 | Kaye Jack, Director | 5,295 | $225.4K | 17 Jun 2026 |
| 17 Jun 2026 | Balachandran Madhavan, Director | 11,685 | $526.5K | 17 Jun 2026 |
| 17 Jun 2026 | Kapusta Matthew C, Officer, Director, CEO AND MANAGING DIRECTOR | 164,429 | $7.1M | 17 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 16 Oct 2026 | JPMORGAN CHASE & CO. | 13G amended | 8.5% | 6.0M |
| 14 Aug 2026 | RTW Investments, LP | 13G | 5.7% | 3.9M |
| 14 Aug 2026 | G1 Execution Services, LLC | 13G amended | 4.8% | 3.3M |
| 20 Jul 2026 | Aberdeen Group plc | 13G amended | 4.52% | 2.8M |
| 16 Jul 2026 | JPMORGAN CHASE & CO | 13G | 7% | 4.9M |
| 15 May 2026 | RTW Investments, LP | 13G amended | 4.1% | 2.6M |
| 12 May 2026 | STATE STREET CORPORATION | 13G | 3.6% | 2.3M |
| 6 May 2026 | FMR LLC | 13G amended | 2.8% | 1.7M |
| 30 Apr 2026 | Aberdeen Group plc | 13G amended | 8.49% | 5.3M |
| 17 Feb 2026 | RTW Investments, LP | 13G amended | 6% | 3.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 8.7M | +0.12% | 3.84 |
| 30 Sep 2026 | 8.7M | -12.14% | 1.94 |
| 15 Sep 2026 | 9.9M | +0.47% | 8.14 |
| 31 Aug 2026 | 9.9M | -8.32% | 9.42 |
| 14 Aug 2026 | 10.8M | +0.81% | 9.84 |
| 31 Jul 2026 | 10.7M | +3.05% | 6.79 |
| 15 Jul 2026 | 10.4M | -9.8% | 7.12 |
| 30 Jun 2026 | 11.5M | -2.63% | 2.57 |
Funds that hold it
From each fund's latest Form 13F.
304 funds held it at 30 Jun 2026: 168 added and 59 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Avoro Capital Advisors LLC | 6,727,777 | $309.9M | +768,182 |
| JPMorgan Chase & Co. | 4,867,755 | $230.8M | +2,030,289 |
| RTW Investments, LP | 3,941,572 | $181.5M | +1,355,216 |
| State Street Corp. | 2,903,825 | $133.8M | +643,313 |
| Aberdeen Group plc | 2,848,117 | $131.2M | -2,458,269 |
| BlackRock, Inc. | 1,877,453 | $86.5M | +143,995 |
| Orbimed Advisors LLC | 1,807,486 | $83.3M | -328,663 |
| Jane Street Group, LLC | 1,610,483 | $74.2M | +974,488 |
| Jennison Associates LLC | 1,561,412 | $71.9M | +327,623 |
| Boxer Capital Management, LLC | 1,503,300 | $69.2M | +841,300 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B